表紙
市場調查報告書

全球裘馨氏肌肉萎縮症(DMD)治療市場:各治療方法、治療類型、終端用戶、地區(2018年∼2023年)

Duchenne Muscular Dystrophy Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 704957
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
價格
全球裘馨氏肌肉萎縮症(DMD)治療市場:各治療方法、治療類型、終端用戶、地區(2018年∼2023年) Duchenne Muscular Dystrophy Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年06月01日內容資訊: 英文 115 Pages
簡介

全球裘馨氏肌肉萎縮症(DMD)治療市場,預計從2018年到2023年的整個預測期內以超越40%的年複合成長率發展。

本報告提供全球裘馨氏肌肉萎縮症(DMD)治療市場調查,各治療方法、治療藥類型、終端用戶、地區的市場規模的變化與預測,市場趨勢,市場成長要素及阻礙因素分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係
  • 開發平台分析

第6章 成長要素,阻礙因素,市場機會,課題(DROC)

  • 市場成長要素
    • 裘馨氏肌肉萎縮症(DMD)的疾病負擔的上升
    • 生物製藥企業的研究開發的投資增加
    • 裘馨氏肌肉萎縮症(DMD)的認識度提高
  • 市場阻礙因素
    • 在全分期中測量臨床效果的標準的缺乏
    • 高的產品成本和嚴格法規
  • 市場機會
  • 課題

第7章 市場區隔

  • 各治療法
    • 分子標靶治療
    • 類固醇法
    • 其他
  • 各治療藥類型
    • 皮質類固醇
    • 非類固醇消炎劑(NSAIDs)
    • 其他
  • 各終端用戶
    • 醫院/診療所
    • 門診中心
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • M&A分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • BioMarin
  • Bristol-Myers Squibb
  • Fibrogen Inc
  • Marathon Pharmaceuticals
  • Nobelpharma Co., Ltd
  • NS Pharma,Inc
  • Pfizer Inc.
  • PTC Therapeutics
  • Santhera Pharmaceuticals
  • Sarepta Therapeutics

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 62903

The propelling factors for the growth of the Duchenne muscular dystrophy (DMD) treatment market include the rising disease burden of Duchenne muscular dystrophy, increasing investments in biopharmaceutical R&D to release novel disease therapies, and increasing awareness campaigns for DMD.

Currently, there is an increase in the number of clinical trials for testing the future treatment for Duchenne muscular dystrophy. The only accepted pharmacological therapy for the treatment of DMD is corticosteroid-based anti-inflammatory treatment. The pharmaceutical drug discovery and development have also grown rapidly in the past few years. As there have been great breakthroughs in technology in the last few years that may facilitate research processes and as the explosion of science in understanding the causes of diseases has made target selection more rational than ever, almost all major companies are now concentrating on R&D, which is likely to have a major impact on the market in the coming years.

Furthermore, with increasing awareness among people and with the government's urgency for the treatment of the disease, there is a big opportunity for the companies to conduct their trails and for new drugs launches, due to which, the market is expected to grow in the coming years.

Key Market Trends

Exon-skipping Segment is Expected to Dominate Duchenne Muscular Dystrophy Treatment Market

Duchenne muscular dystrophy is mostly caused by the internal deletions in the gene for dystrophin, a protein essential for maintaining muscle cell membrane integrity. One of the potential therapeutic method is to mask an exon close to the site where the others are missing, so that the remaining exons can join together. Exon-skipping approach signifies one of the most capable therapeutic approaches that aim to restore the expression of a shorter but functional dystrophin protein.

Moreover, market players are focusing on frequent launches in exon skipping technology which is a significant factor driving the segment thereby propelling the market growth. For instance, In December 2019, Sarepta's exon skipping drug, VYONDYS 53 (golodirsen) has been approved by the Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy.

North American Region holds the Largest Market Share and is Believed to Follow the Same Trend Over the Forecast Period

North America dominates the global Duchenne muscular dystrophy market, due to new product innovations, high healthcare expenditure, and government awareness programs. The United States has dominated the regional market and is projected to maintain its lead, owing to the rising disease incidence and anticipated launch of promising pipeline candidates. In addition, the market is expected to grow with increasing clinical trials around the world, especially in the United States and Europe. According to the FDA in 2017, the Emflaza (deflazacort) tablets and oral suspension were approved to treat DMD patients aged 5 years and above. Emflaza is a corticosteroid that works by decreasing inflammation and reducing the activity of the immune system.

Competitive Landscape

With increasing campaigns and awareness programs, the number of patients is expected to come down, and hence, many companies are conducting campaign programs that help to improve focus on medicines for DMD treatment. There are also very few companies for new drug research for rare diseases because it needs bigger funds. Therefore, the market is not well established in many other therapeutic areas. However, it is expected to experience high growth and expand during the forecast period.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Disease Burden of Duchenne Muscular Dystrophy (DMD)
    • 4.2.2 Increasing Investments in Research and Development of Novel Therapies for DMD
    • 4.2.3 Increasing Awareness Campaigns for DMD
  • 4.3 Market Restraints
    • 4.3.1 Lack of Standardization to Measure Clinical Efficacy Across All Stages of DMD
    • 4.3.2 Stringent Regulatory Framework
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Therapeutic Approaches
    • 5.1.1 Molecular-based Therapies
      • 5.1.1.1 Mutation Suppression
      • 5.1.1.2 Exon Skipping
    • 5.1.2 Steroid Therapy
      • 5.1.2.1 Corticosteroids
    • 5.1.3 Other Therapeutic Approaches
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East & Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East & Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 BioMarin
    • 6.1.2 Fibrogen Inc.
    • 6.1.3 Nobelpharma Co. Ltd
    • 6.1.4 NS Pharma Inc.
    • 6.1.5 Pfizer Inc.
    • 6.1.6 PTC Therapeutics
    • 6.1.7 Santhera Pharmaceuticals
    • 6.1.8 Sarepta Therapeutics
    • 6.1.9 F. Hoffmann-La Roche AG
    • 6.1.10 ReveraGen BioPharma

7 MARKET OPPORTUNITIES AND FUTURE TRENDS